Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lifted by Arlington Financial Advisors LLC

Arlington Financial Advisors LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 44,801 shares of the biopharmaceutical company’s stock after acquiring an additional 1,678 shares during the period. Arlington Financial Advisors LLC’s holdings in Gilead Sciences were worth $3,282,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Tompkins Financial Corp boosted its holdings in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the period. Fortitude Family Office LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $29,000. Private Wealth Management Group LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $29,000. Sachetta LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $30,000. Finally, Rakuten Securities Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $33,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GILD has been the subject of several research reports. Robert W. Baird restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Thursday, June 20th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $74.00 target price on shares of Gilead Sciences in a research note on Friday, June 14th. Wells Fargo & Company reduced their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. UBS Group reduced their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Finally, Barclays reduced their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 29th. Twelve equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Hold” and a consensus price target of $83.47.

Gilead Sciences Stock Performance

GILD stock traded down $0.22 on Friday, reaching $68.61. 9,590,049 shares of the company were exchanged, compared to its average volume of 9,497,302. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $87.86. The stock’s fifty day moving average price is $65.98 and its 200 day moving average price is $72.51. The firm has a market capitalization of $85.48 billion, a PE ratio of 190.58, a PEG ratio of 2.92 and a beta of 0.20. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same quarter in the previous year, the firm posted $1.37 earnings per share. Gilead Sciences’s revenue was up 5.3% compared to the same quarter last year. On average, research analysts anticipate that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.49%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.